Lenogastrim ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
28 | 全身性アミロイドーシス | 1 |
28. 全身性アミロイドーシス
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-006395-37-GB (EUCTR) | 06/09/2007 | 31/07/2007 | A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy - UK Amyloidosis Treatment Trial (UKATT) | A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy - UK Amyloidosis Treatment Trial (UKATT) | The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively disrupt tissue structure and impair function. MedDRA version: 9.1;Level: LLT;Classification code 10002022;Term: Amyloidosis | Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Product Name: Dexamethasone INN or Proposed INN: DEXAMETHASONE Product Name: Dexamethasone INN or Proposed INN: DEXAMETHASONE Trade Name: Lenogastrim Other descriptive name: GRANULOCYTE COLONY STIMULATING FACTOR Product Name: Melphalan INN or Proposed INN: MELPHALAN | Joint UCLH and UCL Biomedical Research Unit | NULL | Not Recruiting | Female: yes Male: yes | 48 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom |